<!DOCTYPE html>
<html lang="zh-TW" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>巴菲特AI價值投資-Johnson & Johnson 2025Q2 財務分析報告</title>
    <!-- 導入 Tailwind CSS -->
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- 導入 Chart.js -->
    <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
    <style>
        /* 自定義樣式 */
        body {
            font-family: 'Inter', 'Noto Sans TC', sans-serif;
        }
        /* 導航列 Active 狀態樣式 */
        .active-nav-link {
            color: #0ea5e9; /* sky-500 */
            font-weight: 600;
            border-bottom: 2px solid #0ea5e9;
        }
        .inactive-nav-link {
            color: #44403c; /* stone-700 */
            border-bottom: 2px solid transparent;
        }
        /* 表格標頭固定 */
        .sticky-header th {
            position: sticky;
            top: 0;
            background-color: #f0f9ff; /* sky-50 */
        }
    </style>
</head>
<body class="bg-stone-50 text-stone-800">

    <!-- Header & Navigation -->
    <header id="header" class="bg-white/80 backdrop-blur-lg shadow-md sticky top-0 z-50 transition-all duration-300">
        <div class="container mx-auto px-6 py-4 flex justify-between items-center">
            <h1 class="text-2xl font-bold text-sky-600">嬌生 (J&J) 2025Q2</h1>
            <!-- Desktop Navigation -->
            <nav class="hidden md:flex space-x-6 items-center">
                <a href="#overview" class="nav-link inactive-nav-link pb-1 transition-colors duration-300 hover:text-sky-500">公司概況</a>
                <a href="#strategy" class="nav-link inactive-nav-link pb-1 transition-colors duration-300 hover:text-sky-500">業務策略</a>
                <a href="#metrics" class="nav-link inactive-nav-link pb-1 transition-colors duration-300 hover:text-sky-500">營運指標</a>
                <a href="#finance" class="nav-link inactive-nav-link pb-1 transition-colors duration-300 hover:text-sky-500">財務表現</a>
                <a href="#investment" class="nav-link inactive-nav-link pb-1 transition-colors duration-300 hover:text-sky-500">投資與流動性</a>
                <a href="#competition" class="nav-link inactive-nav-link pb-1 transition-colors duration-300 hover:text-sky-500">競爭分析</a>
                <a href="#risk" class="nav-link inactive-nav-link pb-1 transition-colors duration-300 hover:text-sky-500">風險因素</a>
                <a href="#summary" class="nav-link inactive-nav-link pb-1 transition-colors duration-300 hover:text-sky-500">數據匯總</a>
                <a href="#recommendation" class="nav-link inactive-nav-link pb-1 transition-colors duration-300 hover:text-sky-500">綜合評估</a>
            </nav>
            <!-- Mobile Menu Button -->
            <div class="md:hidden">
                <button id="mobile-menu-button" class="text-stone-800 focus:outline-none">
                    <svg class="w-6 h-6" fill="none" stroke="currentColor" viewBox="0 0 24 24" xmlns="http://www.w3.org/2000/svg">
                        <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16m-7 6h7"></path>
                    </svg>
                </button>
            </div>
        </div>
        <!-- Mobile Navigation -->
        <div id="mobile-menu" class="hidden md:hidden bg-white border-t border-stone-200">
            <a href="#overview" class="block py-3 px-6 text-stone-700 hover:bg-sky-50">公司概況</a>
            <a href="#strategy" class="block py-3 px-6 text-stone-700 hover:bg-sky-50">業務策略</a>
            <a href="#metrics" class="block py-3 px-6 text-stone-700 hover:bg-sky-50">營運指標</a>
            <a href="#finance" class="block py-3 px-6 text-stone-700 hover:bg-sky-50">財務表現</a>
            <a href="#investment" class="block py-3 px-6 text-stone-700 hover:bg-sky-50">投資與流動性</a>
            <a href="#competition" class="block py-3 px-6 text-stone-700 hover:bg-sky-50">競爭分析</a>
            <a href="#risk" class="block py-3 px-6 text-stone-700 hover:bg-sky-50">風險因素</a>
            <a href="#summary" class="block py-3 px-6 text-stone-700 hover:bg-sky-50">數據匯總</a>
            <a href="#recommendation" class="block py-3 px-6 text-stone-700 hover:bg-sky-50">綜合評估</a>
        </div>
    </header>

    <!-- Main Content -->
    <main class="container mx-auto px-6 py-12">
        
        <!-- 公司營運概況 -->
        <section id="overview" class="scroll-mt-24 mb-16">
            <h2 class="text-3xl font-bold text-stone-800 mb-6 border-b-2 border-sky-500 pb-2">公司營運概況</h2>
            <div class="bg-white rounded-lg shadow-lg p-6 mb-6">
                <p class="text-lg leading-relaxed">嬌生公司 (Johnson & Johnson) 經過業務重組，現已聚焦於兩大核心事業部門：<strong class="text-sky-600">創新藥品 (Innovative Medicine)</strong> 與 <strong class="text-teal-600">醫療科技 (MedTech)</strong>。原民生消費品業務已於2023年分拆為獨立公司 (Kenvue)。嬌生採取跨國多元化經營模式，業務遍及全球超過60個國家，其中美國為最大單一市場，貢獻過半營收，形成了穩固的多角化收入結構。</p>
            </div>
            <div class="grid md:grid-cols-2 gap-6">
                <div class="bg-white rounded-lg shadow-lg p-6">
                    <h3 class="text-2xl font-semibold text-sky-700 mb-3">創新藥品事業</h3>
                    <p>專注於創新藥物的研發、生產與行銷，涵蓋腫瘤、免疫、神經科學、心血管等治療範疇。透過高研發投入和策略性收購，持續推出重磅藥物。2025上半年，此部門營收約佔公司總收入的 2/3。</p>
                </div>
                <div class="bg-white rounded-lg shadow-lg p-6">
                    <h3 class="text-2xl font-semibold text-teal-700 mb-3">醫療科技事業</h3>
                    <p>涵蓋醫療器材、設備和技術方案，包括骨科植入、外科手術、心血管科技及眼科保健等。透過旗下 DePuy Synthes、Ethicon 等子品牌佔有重要市場地位，並積極透過併購強化技術版圖。2025上半年營收約佔總收入的 1/3。</p>
                </div>
            </div>
        </section>

        <!-- 業務策略和發展 -->
        <section id="strategy" class="scroll-mt-24 mb-16">
            <h2 class="text-3xl font-bold text-stone-800 mb-6 border-b-2 border-sky-500 pb-2">業務策略和發展</h2>
            <div class="bg-white rounded-lg shadow-lg p-6 mb-6">
                <h3 class="text-2xl font-semibold text-stone-700 mb-4">核心產品與研發亮點</h3>
                <p class="mb-4">嬌生聚焦於高附加價值的專利藥物與前沿醫療技術，透過內部研發和外部收購雙管齊下，維持產品線的廣度與深度，提供「全方位解決方案」。</p>
                
                <div class="space-y-4">
                    <div>
                        <h4 class="text-xl font-bold text-sky-600">Darzalex (達雷木單抗)</h4>
                        <p>針對多發性骨髓瘤的領導藥物，2025年Q2銷售額達35億美元級別，保持雙位數增長，持續擴大一線治療市佔率。</p>
                    </div>
                    <div>
                        <h4 class="text-xl font-bold text-sky-600">Carvykti (CAR-T療法)</h4>
                        <p>用於多發性骨髓瘤的細胞治療產品，Q2收入達4.39億美元，年增率超過100%，展現治癒潛力。</p>
                    </div>
                     <div>
                        <h4 class="text-xl font-bold text-teal-600">心血管介入裝置</h4>
                        <p>透過收購 Abiomed (Impella 心臟幫浦) 和 Shockwave Medical (血管內震波碎石技術)，成為心血管微創治療的領導者，Q2業務營收猛增22%。</p>
                    </div>
                    <div>
                        <h4 class="text-xl font-bold text-teal-600">機器人手術 OTTAVA</h4>
                        <p>全新一代軟組織手術機器人系統，已在美國完成首批臨床案例，是挑戰現有市場龍頭的關鍵佈局。</p>
                    </div>
                </div>
            </div>
        </section>

        <!-- 互動式產品表現表格 -->
        <section id="product-table-section" class="scroll-mt-24 mb-16">
            <h2 class="text-3xl font-bold text-stone-800 mb-6 border-b-2 border-sky-500 pb-2">重點產品表現 (2025 Q2)</h2>
            <div class="bg-white rounded-lg shadow-lg p-6">
                <div class="mb-4">
                    <input type="text" id="productFilter" class="w-full md:w-1/3 p-2 border border-stone-300 rounded-md focus:ring-2 focus:ring-sky-500 focus:border-sky-500" placeholder="篩選產品名稱或領域...">
                </div>
                <div class="overflow-x-auto">
                    <table class="w-full text-left border-collapse">
                        <thead>
                            <tr class="sticky-header">
                                <th class="p-3 font-semibold text-sm text-stone-600 uppercase border-b-2 border-stone-200">產品名稱</th>
                                <th class="p-3 font-semibold text-sm text-stone-600 uppercase border-b-2 border-stone-200">治療領域</th>
                                <th class="p-3 font-semibold text-sm text-stone-600 uppercase border-b-2 border-stone-200">Q2 銷售額 (億美元)</th>
                                <th class="p-3 font-semibold text-sm text-stone-600 uppercase border-b-2 border-stone-200">年增長率</th>
                            </tr>
                        </thead>
                        <tbody id="productTableBody">
                            <!-- JavaScript will populate this -->
                        </tbody>
                    </table>
                </div>
            </div>
        </section>

        <!-- 營運指標 -->
        <section id="metrics" class="scroll-mt-24 mb-16">
            <h2 class="text-3xl font-bold text-stone-800 mb-6 border-b-2 border-sky-500 pb-2">營運指標 (2025 上半年)</h2>
            <div class="grid md:grid-cols-2 lg:grid-cols-4 gap-6">
                <div class="bg-sky-100 rounded-lg shadow-lg p-6 text-center">
                    <h3 class="text-4xl font-bold text-sky-800">$456.36億</h3>
                    <p class="text-stone-600 mt-2">上半年總營收</p>
                </div>
                <div class="bg-teal-100 rounded-lg shadow-lg p-6 text-center">
                    <h3 class="text-4xl font-bold text-teal-800">+4.1%</h3>
                    <p class="text-stone-600 mt-2">總營收年增長</p>
                </div>
                <div class="bg-amber-100 rounded-lg shadow-lg p-6 text-center">
                    <h3 class="text-4xl font-bold text-amber-800">$134.05億</h3>
                    <p class="text-stone-600 mt-2">調整後淨利</p>
                </div>
                <div class="bg-rose-100 rounded-lg shadow-lg p-6 text-center">
                    <h3 class="text-4xl font-bold text-rose-800">$5.54</h3>
                    <p class="text-stone-600 mt-2">調整後每股盈餘 (EPS)</p>
                </div>
            </div>
        </section>

        <!-- 財務表現細節 -->
        <section id="finance" class="scroll-mt-24 mb-16">
            <h2 class="text-3xl font-bold text-stone-800 mb-6 border-b-2 border-sky-500 pb-2">財務表現細節</h2>
            <div class="grid lg:grid-cols-5 gap-6">
                <div class="lg:col-span-2 bg-white rounded-lg shadow-lg p-6">
                    <h3 class="text-2xl font-semibold text-stone-700 mb-4">營收分析</h3>
                    <p class="mb-4">2025上半年營收穩健成長，Q2增速明顯加快。主要動能來自核心藥品與醫療器材新品放量，以及併購業務貢獻，成功抵銷了王牌藥物 Stelara 專利到期帶來的衝擊。</p>
                    <ul class="list-disc list-inside space-y-2 text-stone-700">
                        <li><strong class="font-semibold">創新藥品:</strong> 扣除Stelara後，Q2業務實現了<span class="text-green-600 font-bold">15.5%</span>的強勁成長。</li>
                        <li><strong class="font-semibold">醫療科技:</strong> Q2營運基礎成長<span class="text-green-600 font-bold">6.1%</span>，心血管業務猛增22%。</li>
                        <li><strong class="font-semibold">毛利率:</strong> 上半年綜合毛利率約67.2%，因高毛利的Stelara銷售驟減而略有下降。</li>
                    </ul>
                </div>
                <div class="lg:col-span-3 bg-white rounded-lg shadow-lg p-6">
                    <h3 class="text-2xl font-semibold text-stone-700 mb-4">2025 Q2 各部門營收貢獻 (億美元)</h3>
                    <div class="relative h-80 w-full">
                        <canvas id="revenueChart"></canvas>
                    </div>
                </div>
            </div>
        </section>

        <!-- 投資和流動性 -->
        <section id="investment" class="scroll-mt-24 mb-16">
            <h2 class="text-3xl font-bold text-stone-800 mb-6 border-b-2 border-sky-500 pb-2">投資和流動性</h2>
            <div class="bg-white rounded-lg shadow-lg p-6">
                <p class="mb-4">嬌生維持強勁的財務狀況，擁有充裕的現金流以支持持續的股息發放和策略性投資。</p>
                <div class="grid md:grid-cols-3 gap-6 text-center">
                    <div class="bg-stone-100 p-4 rounded-lg">
                        <div class="text-3xl font-bold text-sky-600">AAA</div>
                        <div class="text-stone-600">信用評級</div>
                    </div>
                    <div class="bg-stone-100 p-4 rounded-lg">
                        <div class="text-3xl font-bold text-sky-600">$62億</div>
                        <div class="text-stone-600">上半年自由現金流</div>
                    </div>
                    <div class="bg-stone-100 p-4 rounded-lg">
                        <div class="text-3xl font-bold text-sky-600">63年</div>
                        <div class="text-stone-600">連續提高股息</div>
                    </div>
                </div>
            </div>
        </section>

        <!-- 產業競爭分析 -->
        <section id="competition" class="scroll-mt-24 mb-16">
            <h2 class="text-3xl font-bold text-stone-800 mb-6 border-b-2 border-sky-500 pb-2">產業競爭分析</h2>
            <div class="grid md:grid-cols-2 gap-6">
                <div class="bg-white rounded-lg shadow-lg p-6">
                    <h3 class="text-2xl font-semibold text-sky-700 mb-3">製藥產業</h3>
                    <p>穩居全球前五大處方藥廠，但在腫瘤、免疫等領域面臨輝瑞 (Pfizer)、默沙東 (Merck & Co.)、羅氏 (Roche) 等巨頭的激烈競爭。嬌生憑藉深厚且多元的產品組合，成功抵禦單一藥物專利到期的風險。</p>
                </div>
                <div class="bg-white rounded-lg shadow-lg p-6">
                    <h3 class="text-2xl font-semibold text-teal-700 mb-3">醫療器材產業</h3>
                    <p>位居全球前三大醫療器材公司，與美敦力 (Medtronic)、雅培 (Abbott) 等分庭抗禮。在骨科、手術機器人等領域面臨史賽克 (Stryker)、波士頓科學等強勁對手。競爭策略為提供「一站式」整體方案及透過收購獲取新技術。</p>
                </div>
            </div>
        </section>

        <!-- 風險和不確定性 -->
        <section id="risk" class="scroll-mt-24 mb-16">
            <h2 class="text-3xl font-bold text-stone-800 mb-6 border-b-2 border-sky-500 pb-2">風險和不確定性</h2>
            <div class="bg-white rounded-lg shadow-lg p-6">
                <ul class="space-y-4">
                    <li class="flex items-start">
                        <svg class="w-6 h-6 text-red-500 mr-3 flex-shrink-0" fill="none" stroke="currentColor" viewBox="0 0 24 24" xmlns="http://www.w3.org/2000/svg"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z"></path></svg>
                        <div>
                            <h4 class="font-semibold">藥品定價壓力</h4>
                            <p>全球醫保控費趨勢持續，美國《降低通脹法》(IRA) 的藥價談判及中國的集中採購政策，可能對部分產品的利潤率造成壓力。</p>
                        </div>
                    </li>
                    <li class="flex items-start">
                        <svg class="w-6 h-6 text-red-500 mr-3 flex-shrink-0" fill="none" stroke="currentColor" viewBox="0 0 24 24" xmlns="http://www.w3.org/2000/svg"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z"></path></svg>
                        <div>
                            <h4 class="font-semibold">法律訴訟風險</h4>
                            <p>特別是關於爽身粉 (滑石粉) 的訴訟仍在進行中，未來可能需要支付大額和解金，但預計對公司財務根本影響有限。</p>
                        </div>
                    </li>
                    <li class="flex items-start">
                        <svg class="w-6 h-6 text-red-500 mr-3 flex-shrink-0" fill="none" stroke="currentColor" viewBox="0 0 24 24" xmlns="http://www.w3.org/2000/svg"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z"></path></svg>
                        <div>
                            <h4 class="font-semibold">研發不確定性</h4>
                            <p>新藥研發管線若有重大挫折，如臨床試驗失敗或審批延誤，可能對市場信心造成打擊。</p>
                        </div>
                    </li>
                </ul>
            </div>
        </section>

        <!-- 關鍵數據匯總及財務指引 -->
        <section id="summary" class="scroll-mt-24 mb-16">
            <h2 class="text-3xl font-bold text-stone-800 mb-6 border-b-2 border-sky-500 pb-2">關鍵數據匯總及財務指引</h2>
            <div class="bg-white rounded-lg shadow-lg p-6">
                <h3 class="text-2xl font-semibold text-stone-700 mb-4">2025 全年財務指引 (已上調)</h3>
                <div class="grid md:grid-cols-2 gap-6">
                    <div class="bg-sky-50 p-4 rounded-lg">
                        <p class="text-stone-600">全年預估營收</p>
                        <div class="text-3xl font-bold text-sky-700">$932 - $936 億</div>
                    </div>
                    <div class="bg-sky-50 p-4 rounded-lg">
                        <p class="text-stone-600">全年預估調整後 EPS</p>
                        <div class="text-3xl font-bold text-sky-700">約 $10.85</div>
                    </div>
                </div>
                <p class="mt-6 text-lg">管理層強調，公司已連續兩季克服 Stelara 數十億級銷售流失仍維持整體增長，彰顯了業務組合的深度和革新能力，並對下半年及全年表現抱持信心。</p>
            </div>
        </section>

        <!-- 綜合評估-->
        <section id="recommendation" class="scroll-mt-24">
            <h2 class="text-3xl font-bold text-stone-800 mb-6 border-b-2 border-sky-500 pb-2">綜合評估</h2>
            <div class="bg-white rounded-lg shadow-lg p-8">
                <div class="text-center mb-6">
                    <span class="text-2xl font-bold bg-green-100 text-green-800 px-4 py-2 rounded-full">買進並長期持有 (Buy & Hold)</span>
                </div>
                <p class="text-lg leading-relaxed mb-4">嬌生呈現出典型的<strong class="text-sky-600">價值型藍籌股</strong>特徵，擁有穩定的現金流、強健的獲利能力和優厚的股息回報。其當前估值相對合理，動態本益比僅約15倍，股息殖利率約3.4%，適合追求穩健、收益導向的投資人。</p>
                <div class="mt-6 border-t pt-6">
                    <h4 class="text-xl font-semibold mb-3">適合的投資人族群：</h4>
                    <ul class="list-disc list-inside space-y-2">
                        <li><strong>保守型/收入導向投資人：</strong>追求穩定現金流與資產保值，嬌生的高股息與防禦性特質是理想選擇。</li>
                        <li><strong>長線價值投資人：</strong>注重企業基本面，目前估值具吸引力，可享受複利增長和穩定回報。</li>
                        <li><strong>穩健成長型投資人：</strong>兼顧成長性與風險控制，隨著新品上市，未來營收與獲利增速有望提升。</li>
                    </ul>
                </div>
            </div>
        </section>

    </main>

    <!-- Footer -->
    <footer class="bg-stone-800 text-white mt-16">
        <div class="container mx-auto px-6 py-4 text-center">
            <p>&copy; 巴菲特AI價值投資-Johnson & Johnson 2025Q2 財務分析報告。僅供參考，不構成投資建議。</p>
            <p class="text-xs mt-1">資料來源：基於網路中Johnson & Johnson相關公開資料 (2025年8月22日)。</p>
        </div>
    </footer>

    <script>
        document.addEventListener('DOMContentLoaded', function () {
            // --- Mobile Menu Toggle ---
            const mobileMenuButton = document.getElementById('mobile-menu-button');
            const mobileMenu = document.getElementById('mobile-menu');
            mobileMenuButton.addEventListener('click', () => {
                mobileMenu.classList.toggle('hidden');
            });
            // Close mobile menu on link click
            document.querySelectorAll('#mobile-menu a').forEach(link => {
                link.addEventListener('click', () => {
                    mobileMenu.classList.add('hidden');
                });
            });

            // --- Interactive Table Data and Filtering ---
            const productData = [
                { name: 'Darzalex', area: '多發性骨髓瘤', sales: 35.0, growth: '+21.5%' },
                { name: 'Carvykti', area: '多發性骨髓瘤 (細胞治療)', sales: 4.39, growth: '>+100%' },
                { name: 'Tremfya', area: '自體免疫疾病', sales: 'N/A', growth: '+30.1%' },
                { name: 'Stelara', area: '自體免疫疾病', sales: 'N/A', growth: '-43.2%' },
                { name: 'Erleada', area: '前列腺癌', sales: 'N/A', growth: '+21.0%' },
                { name: 'Rybrevant+Lazertinib', area: '肺癌', sales: 1.79, growth: '>+100%' },
                { name: 'Spravato', area: '抗憂鬱劑', sales: 'N/A', growth: '+53.0%' },
                { name: '心血管介入裝置', area: '醫療科技', sales: 'N/A', growth: '+22.0%' },
                { name: '眼科保健', area: '醫療科技', sales: 'N/A', growth: '近雙位數' },
                { name: '外科手術器械', area: '醫療科技', sales: 'N/A', growth: '~+7.0%' },
            ];

            const tableBody = document.getElementById('productTableBody');
            const productFilter = document.getElementById('productFilter');

            function renderTable(data) {
                tableBody.innerHTML = '';
                data.forEach(product => {
                    const growthClass = product.growth.startsWith('-') ? 'text-red-600' : 'text-green-600';
                    const row = `
                        <tr class="hover:bg-stone-50">
                            <td class="p-3 border-b border-stone-200 font-medium">${product.name}</td>
                            <td class="p-3 border-b border-stone-200">${product.area}</td>
                            <td class="p-3 border-b border-stone-200">${typeof product.sales === 'number' ? product.sales.toFixed(2) : product.sales}</td>
                            <td class="p-3 border-b border-stone-200 font-semibold ${growthClass}">${product.growth}</td>
                        </tr>
                    `;
                    tableBody.innerHTML += row;
                });
            }

            productFilter.addEventListener('keyup', () => {
                const searchTerm = productFilter.value.toLowerCase();
                const filteredData = productData.filter(product => 
                    product.name.toLowerCase().includes(searchTerm) || 
                    product.area.toLowerCase().includes(searchTerm)
                );
                renderTable(filteredData);
            });

            renderTable(productData); // Initial render

            // --- Chart.js Revenue Chart ---
            const ctx = document.getElementById('revenueChart').getContext('2d');
            new Chart(ctx, {
                type: 'bar',
                data: {
                    labels: ['創新藥品', '醫療科技', 'Stelara (已包含在藥品中)'],
                    datasets: [{
                        label: '2025 Q2 營收 (億美元)',
                        data: [152, 85, -11.7], // Stelara's decline is represented as a negative impact for context
                        backgroundColor: [
                            'rgba(14, 165, 233, 0.6)', // sky-500
                            'rgba(13, 148, 136, 0.6)', // teal-600
                            'rgba(220, 38, 38, 0.6)'    // red-600
                        ],
                        borderColor: [
                            'rgba(14, 165, 233, 1)',
                            'rgba(13, 148, 136, 1)',
                            'rgba(220, 38, 38, 1)'
                        ],
                        borderWidth: 1
                    }]
                },
                options: {
                    responsive: true,
                    maintainAspectRatio: false,
                    scales: {
                        y: {
                            beginAtZero: true,
                            title: {
                                display: true,
                                text: '營收 (億美元)'
                            }
                        }
                    },
                    plugins: {
                        legend: {
                            display: false
                        },
                        tooltip: {
                            callbacks: {
                                label: function(context) {
                                    let label = context.dataset.label || '';
                                    if (label) {
                                        label += ': ';
                                    }
                                    if (context.parsed.y !== null) {
                                        if (context.label === 'Stelara (已包含在藥品中)') {
                                            label = `Stelara 銷售下滑影響: ${context.parsed.y} 億美元`;
                                        } else {
                                            label += `${context.parsed.y} 億美元`;
                                        }
                                    }
                                    return label;
                                }
                            }
                        }
                    }
                }
            });

            // --- Intersection Observer for Active Nav Link ---
            const sections = document.querySelectorAll('section');
            const navLinks = document.querySelectorAll('nav a.nav-link');

            const observerOptions = {
                root: null,
                rootMargin: '0px',
                threshold: 0.4 // 40% of the section must be visible
            };

            const observer = new IntersectionObserver((entries, observer) => {
                entries.forEach(entry => {
                    if (entry.isIntersecting) {
                        const id = entry.target.getAttribute('id');
                        navLinks.forEach(link => {
                            link.classList.remove('active-nav-link');
                            link.classList.add('inactive-nav-link');
                            if (link.getAttribute('href') === `#${id}`) {
                                link.classList.add('active-nav-link');
                                link.classList.remove('inactive-nav-link');
                            }
                        });
                    }
                });
            }, observerOptions);

            sections.forEach(section => {
                observer.observe(section);
            });
        });
    </script>
</body>
</html>